Substantial evidence has shown involvement of PKA/CREB pathway in pathogenesis of PD, and agents augmenting PKA/CREB pathway could protect neurons against MPP+-induced decline of mitochondrial membrane potential, oxidative stress and apoptosis in in vitro, ex vivo and in vivo PD models [43, 44]. This evidence concerns the gene CREB1 and Parkinson disease.